307 related articles for article (PubMed ID: 31573053)
1. Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians.
Likhitsup A; Parikh ND
Pharmacoeconomics; 2020 Jan; 38(1):5-24. PubMed ID: 31573053
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis.
Patel D; Terrault NA; Yao FY; Bass NM; Ladabaum U
Clin Gastroenterol Hepatol; 2005 Jan; 3(1):75-84. PubMed ID: 15645408
[TBL] [Abstract][Full Text] [Related]
3. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances.
Nouso K; Tanaka H; Uematsu S; Shiraga K; Okamoto R; Onishi H; Nakamura S; Kobayashi Y; Araki Y; Aoki N; Shiratori Y
J Gastroenterol Hepatol; 2008 Mar; 23(3):437-44. PubMed ID: 17683496
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns and direct medical costs among patients with advanced hepatocellular carcinoma.
Aly A; Malangone-Monaco E; Noxon V; Henriques C; Benavente F; Kim A
Curr Med Res Opin; 2020 Nov; 36(11):1813-1823. PubMed ID: 32969741
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.
Cammà C; Cabibbo G; Petta S; Enea M; Iavarone M; Grieco A; Gasbarrini A; Villa E; Zavaglia C; Bruno R; Colombo M; Craxì A; ;
Hepatology; 2013 Mar; 57(3):1046-54. PubMed ID: 23299720
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
[TBL] [Abstract][Full Text] [Related]
9. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.
Costentin CE; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Letouzé E; Imbeaud S; Zucman-Rossi J; Audureau E; Roudot-Thoraval F; Nahon P;
Gastroenterology; 2018 Aug; 155(2):431-442.e10. PubMed ID: 29729258
[TBL] [Abstract][Full Text] [Related]
10. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
Trials; 2014 Dec; 15():474. PubMed ID: 25472660
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms.
Parikh ND; Singal AG; Hutton DW; Tapper EB
Am J Gastroenterol; 2020 Oct; 115(10):1642-1649. PubMed ID: 32530829
[TBL] [Abstract][Full Text] [Related]
12. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V
Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556
[TBL] [Abstract][Full Text] [Related]
13. Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma.
Naugler WE; Sonnenberg A
Liver Transpl; 2010 Oct; 16(10):1186-94. PubMed ID: 20879017
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib for the treatment of advanced hepatocellular carcinoma.
Connock M; Round J; Bayliss S; Tubeuf S; Greenheld W; Moore D
Health Technol Assess; 2010 May; 14 Suppl 1():17-21. PubMed ID: 20507799
[TBL] [Abstract][Full Text] [Related]
15. Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy.
Bonafede MM; Korytowsky B; Singh P; Cai Q; Cappell K; Jariwala-Parikh K; Sill B; Parikh ND
J Gastrointest Cancer; 2020 Mar; 51(1):217-226. PubMed ID: 31011982
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis.
Chen S; Peng Z; Wei M; Liu W; Dai Z; Wang H; Mei J; Cheong M; Zhang H; Kuang M
BMC Cancer; 2018 Apr; 18(1):392. PubMed ID: 29621988
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL
J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357
[TBL] [Abstract][Full Text] [Related]
18. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety.
Vitale A; Volk ML; Pastorelli D; Lonardi S; Farinati F; Burra P; Angeli P; Cillo U
Hepatology; 2010 Jan; 51(1):165-73. PubMed ID: 19877181
[TBL] [Abstract][Full Text] [Related]
19. Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare.
Shaya FT; Breunig IM; Seal B; Mullins CD; Chirikov VV; Hanna N
Pharmacoeconomics; 2014 Jan; 32(1):63-74. PubMed ID: 24293197
[TBL] [Abstract][Full Text] [Related]
20. Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it?
Giannini EG; Cucchetti A; Erroi V; Garuti F; Odaldi F; Trevisani F
World J Gastroenterol; 2013 Dec; 19(47):8808-21. PubMed ID: 24379604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
